Rheumnow Podcast ACR24 PsA Topic Panel Advancing Care for Psoriatic Arthritis
Nov 27, 2024
Join Artie Kavanaugh, a rheumatologist from UC San Diego, and Quillen Connelly from Galway Clinic, as they delve into the intricate realm of psoriatic arthritis. They discuss the rising placebo response rates tied to socioeconomic factors and the urgent need for gender-specific research in treatment. Artie breaks down the potential of combination therapies, while Quillen shares insights on the durable effectiveness of bimikizumab. Together, they illuminate the latest advancements in diagnosis and treatment, providing a comprehensive overview for clinicians.
AI Snips
Chapters
Transcript
Episode notes
Rising Placebo Responses
- Placebo responses in psoriatic arthritis trials are increasing, linked to gross national income.
- Higher-income countries show lower placebo responses, potentially impacting study interpretations.
Combination Therapy in PsA
- Combination therapy, particularly TNF inhibitors with JAK inhibitors or biologics, might offer additional efficacy.
- Safety concerns, especially infections, require careful monitoring, potentially through registries.
Sex Differences in PsA
- Sex differences significantly influence psoriatic arthritis presentation, disease course, and treatment response.
- Females often have less severe skin, longer disease duration, higher BMI, and greater impact on quality of life.